BioMarin Pharma (BMRN) Tops Q1 EPS by 39c ; Offers Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.71, $0.39 better than the analyst estimate of $0.32. Revenue for the quarter came in at $649 million versus the consensus estimate of $649.27 million.

GUIDANCE:

BioMarin Pharma sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.75. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.76 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Moody’s raises BJ’s Wholesale outlook to positive on debt reduction